• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Monday, November 8, 2021

    11/2/21 10:00:00 AM ET
    $TCDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TCDA alert in real time by email

    SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its third quarter 2021 financial results after the close of market on Monday, November 8, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its third quarter financial results and business progress. The webcast or call may be accessed as follows:

    Tricida Conference Call Information

    Tricida will host its Third Quarter Financial Results and Business Update Conference Call and webcast on Monday November 8, 2021 at 4:30 pm Eastern Time. The webcast or conference call may be accessed as follows:

    Tricida Conference Call

    Monday, November 8, 2021

    4:30 pm Eastern Time

                      Webcast:  IR.Tricida.com               
     Dial-In:  (877) 377-5478 
     International: (629) 228-0740 
     Conference ID:  8785726 

    A replay of the webcast will be available on Tricida's website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

    About Tricida

    Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. There are currently no therapies approved by the FDA to slow progression of kidney disease by correcting chronic metabolic acidosis in patients with CKD. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

    For more information about Tricida, please visit www.Tricida.com.

    Contact:

    Jackie Cossmon

    Tricida, Inc.

    Senior Vice President of Investor Relations and Communications

    [email protected]

    Source: Tricida, Inc.



    Primary Logo

    Get the next $TCDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCDA

    DatePrice TargetRatingAnalyst
    4/13/2022$25.00Buy
    Goldman
    11/16/2021$7.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $TCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Tricida with a new price target

      Goldman initiated coverage of Tricida with a rating of Buy and set a new price target of $25.00

      4/13/22 7:21:51 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida upgraded by JP Morgan with a new price target

      JP Morgan upgraded Tricida from Underweight to Neutral and set a new price target of $7.00

      11/16/21 5:20:40 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care